Remedium Bio, Inc. is a preclinical-stage biotechnology company developing novel gene therapies for a broad range of highly debilitating diseases. The company's R&D approach focuses on modularly combining proven technologies to treat well-characterized disease pathology streamlining elements of the product development process. Remedium's pipeline includes a lead candidate first-in-class, single-injection, potentially disease-modifying gene therapy treatment for the treatment of Osteoarthritis and gene therapy treatments for the management of Diabetes and Stroke.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/15/22 | $2,300,000 |
Angel Star Ventures Apis Health Angels Guindy Alumni Angels Longevitytech.fund MicroVentures Primo Medical Group Sherwood Ventures  | undisclosed | |
| 09/10/24 | undisclosed | Venture |
LifeSpan Vision Ventures | undisclosed |
